To help diagnose the cause of acute hepatitis; as part of a viral hepatitis panel to identify the type of hepatitis virus causing an infection; sometimes to evaluate the need for the hepatitis A vaccine
When you have symptoms of an acute hepatitis infection, such as jaundice, or when you may have been exposed to hepatitis A virus (HAV)
A blood sample drawn from a vein in your arm
Hepatitis A is a highly contagious liver infection caused by the hepatitis A virus (HAV). It is one of several various causes of hepatitis, a condition characterized by inflammation and enlargement of the liver. This test detects antibodies in the blood that are produced by the immune system in response to a hepatitis A infection.
Hepatitis A is one of five "hepatitis viruses" identified so far, including B, C, D, and E, that are known to cause the disease. While hepatitis A can cause a severe, acute disease that typically lasts 1 to 2 months, it does not cause a chronic infection as do some of the other hepatitis viruses.
Hepatitis A is spread, most commonly, from person-to person through stool (fecal) contamination or by ingesting food or water contaminated by the stool of an infected person (a foodborne illness). Recognized risk factors for hepatitis A include close contact with an infected person, international travel, household or personal contact with a child who attends a child care center, household or personal contact with a newly arriving international adoptee, a recognized foodborne outbreak, men who have sex with men, and use of illegal drugs.
Although there are many causes of hepatitis, the symptoms remain the same. In hepatitis, the liver is damaged and unable to function normally. It cannot process toxins or waste products such as bilirubin for their removal from the body. During the course of the disease, bilirubin and liver enzyme levels in the blood can increase. While tests such as bilirubin or a liver panel can tell a healthcare practitioner that someone has hepatitis, they do not identify the cause. Antibody tests for hepatitis viruses may help determine the cause.
There are two different classes of hepatitis A antibody that may be tested, IgM and IgG. When a person is exposed to hepatitis A, the body first produces hepatitis A IgM antibodies. These antibodies typically develop 2 to 3 weeks after first being infected (and are detectable before the onset of symptoms) and persist for about 3 to 6 months. Hepatitis A IgG antibodies are produced within 1 to 2 weeks of the IgM antibodies and usually persist for life. (See below for more details.)
A vaccine that prevents hepatitis A has been available since 1995. Historically, infection rates varied cyclically, with nationwide increases every 10-15 years. However, according to the Centers for Disease Control and Prevention (CDC), hepatitis A rates have declined by more than 95% since the vaccine first became available. In 2015, the number of acute hepatitis A cases reported nationwide was an estimated 2,800.
This test is used to help diagnose a liver infection due to the hepatitis A virus (HAV). There are several causes of hepatitis and the accompanying symptoms, so this test may be used to determine if the symptoms are due to hepatitis A.
A few different versions of the test may be used to detect different classes of hepatitis A antibodies.
In acute hepatitis, other tests such as bilirubin, liver panel, ALT, and AST may be performed with viral hepatitis tests to help diagnose the condition.
Testing for the presence of IgM antibodies to hepatitis A is ordered when someone has acute symptoms such as:
In some people and in many young children, hepatitis A may not cause any symptoms. Children infected by HAV often have very mild symptoms, such as fever and diarrhea, and are often thought to have "flu."
An HAV test may also be ordered when a person is likely to have been exposed to the virus regardless of whether symptoms are present or not.
Results of hepatitis testing may indicate the following:
|HAV IgM||HAV IgG or Total Antibody (IgM and IgG)||Results Indicate|
|Positive||Not Performed||Acute or recent HAV infection|
|Negative||Positive||No active infection but previous HAV exposure; has developed immunity to HAV or recently vaccinated for HAV|
|Not Performed||Positive||Has been exposed to HAV but does not rule out acute infection|
|Not Performed||Negative||No current or previous HAV infection; vaccine may be recommended if at risk|
A total antibody test detects both IgM and IgG antibodies but does not distinguish between them.
If the total antibody test or hepatitis A IgG result is positive and someone has never been vaccinated against HAV, then the person has had past exposure to the virus. About 30% of adults over age 40 have antibodies to hepatitis A.
Hepatitis A vaccines are effective even when administered up to 15 days after exposure to the virus. Infants, immunocompromised people, people with chronic liver disease, or adults over 40 may be given an injection of immune globulin instead of the vaccine for post-exposure protection.
Although hepatitis A IgM antibodies are considered diagnostic for acute infection with hepatitis A, there has been increasing use of the test in people who do not have signs and symptoms of acute hepatitis. The Centers for Disease Control and Prevention have recommended that the test only be used for persons who clinically have acute hepatitis to decrease the possibility of falsely positive results.
The virus is passed through contact with stool (fecal matter) from an infected person, typically via contaminated food or water. If a person infected with HAV does not wash their hands after using the bathroom, that person can pass the virus by handling raw fruits and vegetables consumed by others, or directly through person to person contact. You can also contract the virus by eating raw or improperly cooked seafood that had fed in contaminated waters. You may also contract the virus through sexual contact with someone who is infected but asymptomatic.
According to the World Health Organization, you can spread the disease to others roughly 1 to 3 weeks before symptoms, such as jaundice, begin to appear. Symptoms typically develop within 4 weeks but can appear any time between 2 and 6 weeks after you are first infected. You can continue to be contagious, but less so, for several weeks after jaundice develops.
There is no specific treatment for hepatitis A. Mild forms of the disease usually resolve on their own and leave no lasting damage to the liver. The focus is usually on supportive therapy, making sure you are getting enough fluids and nutrition by eating and drinking small amounts several times a day. In rare cases, fulminant hepatitis, a life-threatening form that causes liver failure, requires hospitalization. Hepatitis A tends to be more severe in the elderly and in those who also have chronic liver disease, so person with acute hepatitis A in those settings should be watched more closely.
Yes. There is a vaccine available. It is recommended that all children be vaccinated at age one year. Any children ages 2-18 who did not receive the vaccine at age one should also receive the vaccine. It is also recommended for people who are at an increased risk of exposure to the virus, such as:
The vaccine is also recommended for those who are at a greater risk for complications from the disease, including people with chronic liver disease and those who have damage to their liver from some other cause.
If it is known that you were exposed to the hepatitis A virus, you may be given the vaccine to prevent the disease.
Hepatitis A can also be prevented with good hygiene. This includes washing hands well after using the bathroom, after changing diapers, and before eating or starting any food preparation.
No, once you have had the disease and develop the IgG class of antibodies, they will provide immunity for the rest of your life.
Sources Used in Current Review
(2017 November 8, Updated). Hepatitis A Questions and Answers for Health Professionals. Centers for Disease Control and Prevention. Available online at https://www.cdc.gov/hepatitis/hav/afaq.htm . Accessed on 3/18/18.
Gilroy, R. (2017 October 16, Updated). Hepatitis A. Medscape Gastroenterology. Available online at https://emedicine.medscape.com/article/177484-overview Accessed on 3/18/18.
Phillips, M. et. al. (2016 August 8, Updated). Hepatitis A. MedlinePlus Medical Encyclopedia. Available online at https://medlineplus.gov/ency/article/000278.htm Accessed on 3/18/18.
(2017 May, Updated). Hepatitis A. National Institute of Diabetes and Digestive and Kidney Diseases. Available online at https://www.niddk.nih.gov/health-information/liver-disease/viral-hepatitis/hepatitis-a. Accessed on 3/18/18.
Genzen, J. et. al. (2018 March, Updated).Hepatitis A Virus – HAV. ARUP Consult. Available online at https://arupconsult.com/content/hepatitis-virus. Accessed on 3/18/18.
(2017 November 2, Updated). Hepatitis A Questions and Answers for the Public. Centers for Disease Control and Prevention. Available online at https://www.cdc.gov/hepatitis/hav/afaq.htm#overview. Accessed on 3/18/18.
(© 1995–2018). Hepatitis A IgM Antibody, Serum. Mayo Clinic Mayo Medical Laboratories. Available online at https://www.mayomedicallaboratories.com/test-catalog/Clinical+and+Interpretive/48064. Accessed on 3/18/18.
Sources Used in Previous Reviews
Clinical Chemistry: Principles, Procedures, Correlations. Michael L. Bishop, Janet L. Duben-Engelkirk, Edward P. Fody. Lipincott Williams & Wilkins, 4th Edition.
(Update August 21, 2009) Lehrer J. Hepatitis A. MedlinePlus Medical Encyclopedia. Available online at http://www.nlm.nih.gov/medlineplus/ency/article/000278.htm. Accessed August 2009.
(Updated June 13, 2008) Centers for Disease Control and Prevention. FAQs for Health Professionals, Hepatitis A. Available online at http://www.cdc.gov/hepatitis/HAV/HAVfaq.htm#general. Accessed August 2009.
(June 24, 2008) CDC. Statistics and Surveillance, Hepatitis A. Available online at http://www.cdc.gov/hepatitis/Statistics.htm. Accessed September 2009.
(Sep. 5, 2009) Mayo Clinic Staff. Hepatitis A. Available online at http://www.mayoclinic.com/health/hepatitis-a/DS00397. Accessed September 2009.
Forbes BA, Sahm DF, Weissfeld AS. Bailey & Scott's Diagnostic Microbiology 12th Edition: Mosby Elevier, St. Louis, MO; 2007, Pp 764-765.
(Updated February 2009) American Academy of Family Physicians. Hepatitis A. Available online at http://familydoctor.org/online/famdocen/home/common/infections/hepatitis/897.html. Accessed August 2009.
Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. Burtis CA, Ashwood ER and Bruns DE, eds. 4th ed. St. Louis, Missouri: Elsevier Saunders; 2006, Pp 1804-1805.
Henry's Clinical Diagnosis and Management by Laboratory Methods. 21st ed. McPherson RA and Pincus MR, eds. Philadelphia: 2007, Pp 271.
Centers for Disease Control and Prevention. FAQs for Health Professionals: Hepatitis A. Available online at http://www.cdc.gov/hepatitis/HAV/HAVfaq.htm. Accessed July 27, 2013.
Center for Disease Control and Prevention. Statistics and Surveillance: Hepatitis A. Available online at http://www.cdc.gov/hepatitis/statistics/2010surveillance/Commentary.htm#analysesI. Accessed July 27, 2013.
Mayo Clinic. Hepatitis A. Available online at http://www.mayoclinic.com/health/hepatitis-a/DS00397. Accessed July 27, 2013.
National Digestive Diseases Information Clearinghouse (NDDIC). Viral Hepatitis: A through E and Beyond. Available online at http://digestive.niddk.nih.gov/ddiseases/pubs/viralhepatitis/index.aspx#hepa. Accessed July 27, 2013.
Fischbach, F.T. (2004). A Manual of Laboratory & Diagnostic Tests. 7th Edition., Lippincott Williams & Wilkins, Philadelphia.
(August 29, 2013) Gilroy R. Hepatitis A. Medscape Reference article. Available online at http://emedicine.medscape.com/article/177484-overview. Accessed August 2013.
(May 19, 2006) Centers for Disease Control and Prevention. Prevention of Hepatitis A Through Active or Passive Immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 55(RR07);1-23. Available online at http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5507a1.htm. Accessed August 2013.
Fiore AF, Wasley A, Bell, BP. Prevention of Hepatitis A Through Active or Passive Immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2006;55(RR07);1-23.
(Updated Apr 11, 2013) Virginia Department of Public Health. Hepatitis A Factsheet. Available online at http://www.vdh.state.va.us/Epidemiology/factsheets/Hepatitis_A.htm. Accessed February 2014.
(©2014) World Health Organization. Hepatitis A. Available online at http://www.who.int/csr/disease/hepatitis/whocdscsredc2007/en/index1.html. Accessed February 2014.
Henry's Clinical Diagnosis and Management by Laboratory Methods. 22nd ed. McPherson R, Pincus M, eds. Philadelphia, PA: Saunders Elsevier: 2011, Pp 305, 1058-1059.